BACKGROUND: CYP17A1 is involved in the steroidogenesis of dehydroepiandrosterone and androstenedione. CYP17A is a target for the hormonal treatment of prostate cancer (PCa). OBJECTIVES: To investigate the role of CYP17A1 as a driver of PCa growth. MATERIALS AND METHODS: We examined the expression of CYP17A1 and of androgen receptors (AR) in PCa specimens and in PCa cell lines. RESULTS: CYP17A1 was strongly expressed in the cytoplasm of PCa cells (median 50% of cancer cells, range 0-100%). The nuclear AR expression in cancer cells was directly related with CYP17A1 (p < 0.0001, r = 0.51). The hormone dependent 22Rv1 cell line expressed the CYP17A1 and AR protein and mRNA, in contrast to the PC3 and DU145 cell lines (p < 0.0001). Testosterone and dexamethasone induced nuclear expression of AR and this effect was abolished by abiraterone. CYP17A1 levels were not affected by the incubation with testosterone, while abiraterone significantly reduced its expression. Abiraterone reduced the growth rate and migration of testosterone stimulated 22Rv1 cells. CONCLUSIONS: CYP17A1 is strongly expressed in half about of human prostate carcinomas, implying an intracellular androgen synthesis by cancer cells. Abiraterone effectively blocked nuclear accumulation of AR and suppressed CYP17A1 expression. CYP17A1 may function as a biomarker to select the best hormonal anticancer therapy.
BACKGROUND: CYP17A1 is involved in the steroidogenesis of dehydroepiandrosterone and androstenedione. CYP17A is a target for the hormonal treatment of prostate cancer (PCa). OBJECTIVES: To investigate the role of CYP17A1 as a driver of PCa growth. MATERIALS AND METHODS: We examined the expression of CYP17A1 and of androgen receptors (AR) in PCa specimens and in PCa cell lines. RESULTS: CYP17A1 was strongly expressed in the cytoplasm of PCa cells (median 50% of cancer cells, range 0-100%). The nuclear AR expression in cancer cells was directly related with CYP17A1 (p < 0.0001, r = 0.51). The hormone dependent 22Rv1 cell line expressed the CYP17A1 and AR protein and mRNA, in contrast to the PC3 and DU145 cell lines (p < 0.0001). Testosterone and dexamethasone induced nuclear expression of AR and this effect was abolished by abiraterone. CYP17A1 levels were not affected by the incubation with testosterone, while abiraterone significantly reduced its expression. Abiraterone reduced the growth rate and migration of testosterone stimulated 22Rv1 cells. CONCLUSIONS: CYP17A1 is strongly expressed in half about of human prostate carcinomas, implying an intracellular androgen synthesis by cancer cells. Abiraterone effectively blocked nuclear accumulation of AR and suppressed CYP17A1 expression. CYP17A1 may function as a biomarker to select the best hormonal anticancer therapy.
Authors: Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher Journal: N Engl J Med Date: 2011-05-26 Impact factor: 91.245
Authors: Philip Cornford; Joaquim Bellmunt; Michel Bolla; Erik Briers; Maria De Santis; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Thomas Wiegel; Nicolas Mottet Journal: Eur Urol Date: 2016-08-31 Impact factor: 20.096
Authors: Jennifer A Locke; Emma S Guns; Amy A Lubik; Hans H Adomat; Stephen C Hendy; Catherine A Wood; Susan L Ettinger; Martin E Gleave; Colleen C Nelson Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: Matias Knuuttila; Emrah Yatkin; Jenny Kallio; Saija Savolainen; Teemu D Laajala; Tero Aittokallio; Riikka Oksala; Merja Häkkinen; Pekka Keski-Rahkonen; Seppo Auriola; Matti Poutanen; Sari Mäkelä Journal: Am J Pathol Date: 2014-06-17 Impact factor: 4.307
Authors: Juliet Richards; Ai Chiin Lim; Colin W Hay; Angela E Taylor; Anna Wingate; Karolina Nowakowska; Carmel Pezaro; Suzanne Carreira; Jane Goodall; Wiebke Arlt; Iain J McEwan; Johann S de Bono; Gerhardt Attard Journal: Cancer Res Date: 2012-03-12 Impact factor: 12.701
Authors: Elahe A Mostaghel; Keith R Solomon; Kristine Pelton; Michael R Freeman; R Bruce Montgomery Journal: PLoS One Date: 2012-01-18 Impact factor: 3.240
Authors: Shuyi Fang; Jake L Owens; Elena Beketova; Sheng Liu; Xufeng Chen; Qingfu Zhang; Andrew M Asberry; Xuehong Deng; Jonathan Malola; Jiaoti Huang; Chenglong Li; Roberto Pili; Bennett D Elzey; Timothy L Ratliff; Jun Wan; Chang-Deng Hu Journal: Cancer Res Date: 2020-09-30 Impact factor: 12.701
Authors: Roberto H Barbier; Edel M McCrea; Kristi Y Lee; Jonathan D Strope; Emily N Risdon; Douglas K Price; Cindy H Chau; William D Figg Journal: Sci Rep Date: 2021-05-24 Impact factor: 4.996
Authors: Sisi Qin; Huanyao Gao; Wootae Kim; Huan Zhang; Yayun Gu; Krishna R Kalari; Jason P Sinnwell; Jodi A Scholz; Fang Xie; Ping Yin; Jia Yu; Bo Qin; Yongxian Zhuang; Lixuan Wei; Winston Tan; Alan H Bryce; Richard M Weinshilboum; Liewei Wang Journal: Clin Pharmacol Ther Date: 2022-04-12 Impact factor: 6.903
Authors: Yuting Shan; Yingbo Huang; Adam M Lee; Joshua Mentzer; Alexander Ling; R Stephanie Huang Journal: Front Oncol Date: 2021-05-21 Impact factor: 6.244